NYMC Faculty Publications
Heart Failure Biomarkers in Patients With Dilated Cardiomyopathy
Author Type(s)
Faculty
DOI
10.1016/j.ijcard.2013.01.157
Journal Title
International Journal of Cardiology
First Page
2404
Last Page
2410
Document Type
Article
Publication Date
10-3-2013
Department
Medicine
Abstract
BACKGROUND: We set out to evaluate the utility of selected heart failure (HF) biomarkers in patients with dilated cardiomyopathy (DCM).
METHODS: In a prospective, randomized study, 68 DCM patients with left ventricular ejection fraction (LVEF) ≤ 40% treated optimally were included. They were observed for 5 years. Initial and control tests included full clinical examination, measurement of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and IL-10, syndecan-4, cystatin C (CysC) and N-terminal pro-brain natriuretic peptide (NT-proBNP), echocardiographic examination, and the assessment of exercise capacity in 6-minute walk test (6MWT).
RESULTS: Finally, after 5-year follow-up we analyzed the data of 45 DCM patients. Concentration of syndecan-4 correlated negatively with LVEF (R=-0.36, p=0.02) and positively with LV systolic (R=0.57, p
CONCLUSIONS: CysC correlates negatively with both kidney function and exercise capacity. Syndecan-4 may be a useful biomarker for predicting adverse LV remodeling in DCM patients.
Recommended Citation
Bielecka-Dabrowa, A., von Haehling, S., Aronow, W. S., Ahmed, M., Rysz, J., & Banach, M. (2013). Heart Failure Biomarkers in Patients With Dilated Cardiomyopathy. International Journal of Cardiology, 168 (3), 2404-2410. https://doi.org/10.1016/j.ijcard.2013.01.157
